SEC Form 4 · accession 0001209191-17-028749

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — CEO & President · Director

Period of report

Apr 28, 2017

Accepted (ET)

Apr 28, 2017 · 4:44 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Apr 28, 2017	M	88,507	$29.98	A	395,152	D
Common Stock	Apr 28, 2017	M	1,527	$34.39	A	396,679	D
Common Stock	Apr 28, 2017	M	20,000	$34.24	A	416,679	D
Common Stock	Apr 28, 2017	M	30,000	$34.05	A	446,679	D
Common Stock^F2,F3	Apr 28, 2017	S	157,200	$119.50	D	289,479	D
Common Stock	holding	—	—		—	440	I	401k

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F4	$29.98	Apr 28, 2017	M	88,507	D	—	Dec 13, 2021	Common Stock	88,507	124,601	D
Stock Option (Right to Buy)^F4	$34.39	Apr 28, 2017	M	1,527	D	—	Dec 14, 2020	Common Stock	1,527	0	D
Stock Option (Right to Buy)^F4	$34.24	Apr 28, 2017	M	20,000	D	—	May 31, 2020	Common Stock	20,000	0	D
Stock Option (Right to Buy)^F4	$34.05	Apr 28, 2017	M	30,000	D	—	Jul 5, 2019	Common Stock	30,000	0	D

F1Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1.
F2Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3Open market sales reported on this line occurred at a weighted average price of $119.50 (range $119.50 to $119.60).
F4Fully vested.